智通财经APP获悉，再鼎医药(09688)再涨超5%，截至发稿，涨5.1%，报15.26港元，成交额8197.41万港元。
消息面上，2月9日，再鼎医药的注射用ZL-1310拟纳入突破性疗法，拟用于一线含铂治疗期间或治疗后出现疾病进展的广泛期小细胞肺癌(ES-SCLC)患者。ZL-1310在早期临床研究中展现出的疗效数据非常突出，尤其是在二线及以上治疗和脑转移患者中均显示出高缓解率，使其有潜力成为SCLC治疗领域的突破性疗法。
海通国际此前发布研报称，公司一方面通过引进并商业化海外产品获取稳定收入，另一方面依托跨境平台推动创新管线全球开发。核心管线中，靶向DLL3的ADC药物Zocilurtatug计划在2026年底前启动三项注册临床，覆盖小细胞肺癌和神经内分泌癌。此外，公司还拥有多款具备差异化潜力的早期全球资产，如ZL-1503、ZL-6201等，共同支撑其长期价值创造。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.